Wedbush Reiterates “Outperform” Rating for Spyre Therapeutics (NASDAQ:SYRE)
Wedbush reissued their outperform rating on shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) in a report released on Monday,RTT News reports. Wedbush currently has a $65.00 price target on the stock. A number of other brokerages also recently commented on SYRE. The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a […]
Wedbush reissued their outperform rating on shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) in a report released on Monday,RTT News reports. Wedbush currently has a $65.00 price target on the stock. A number of other brokerages also recently commented on SYRE. The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a […]
